Kazia Therapeutics' pipeline is validated by recent PI3K/AKT/mTOR pathway approvals and acquisitions.. Read more on KZIA ...
Managing the side effects in patients being treated for metastatic breast cancer can be challenging. Recently, Marla D. Lipsyc-Sharf, MD, a breast medical oncologist and health sciences clinical ...
BM-3103 is a first-in-class topical mTOR inhibitor that promotes autophagy to clear mutant keratin aggregates in epidermolysis bullosa simplex. The Food and Drug Administration (FDA) has granted Fast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results